Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superior efficacy over placebo in reducing pain among patients with fibromyalgia. These findings suggest that CBD should not be routinely recommended as a primary treatment for fibromyalgia pain based on current evidence. Patients and clinicians should weigh these results carefully when considering CBD as part of a fibromyalgia management plan.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomized, controlled trial provides the rigorous evidence needed to determine whether CBD has genuine efficacy for fibromyalgia pain management, addressing current clinical practice that relies on anecdotal reports rather than robust data. Given fibromyalgia’s limited pharmacological treatment options and the growing patient interest in cannabinoid-based therapies, establishing CBD’s efficacy and safety profile could either support its clinical adoption or redirect patients toward evidence-based alternatives. The study’s rigorous methodology (double-blind, placebo-controlled design) helps clinicians distinguish genuine therapeutic effects from placebo response, which is particularly important in pain conditions with high placebo sensitivity.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This Danish randomized controlled trial addresses a meaningful gap by testing cannabidiol against placebo in fibromyalgia patients, a population where evidence-based options remain limited and off-label cannabis use is common. While the study’s double-blind design and placebo control strengthen confidence in any observed effects, single-center enrollment limits generalizability, and we should await the complete results to assess both the magnitude of benefit and the specific pain domains affected, as fibromyalgia’s heterogeneity means responses may vary considerably across patients. The safety profile of CBD also warrants careful review, particularly regarding drug interactions in patients often taking multiple medications for pain, sleep, and mood. Until we see the full data, CBD remains an option to discuss with carefully selected fibromyalgia patients as part of a multimodal approach, but should not yet replace established non-pharmacologic strategies or first-line medications with stronger evidence bases.
|